[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease

Alzheimer's Disease Clinical Trial

Official title:

[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06141356
• Other study ID #: ZineAD
• Status: Recruiting
• Start date: January 30, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: November 2023
• Source: Peking Union Medical College Hospital
• Contact: Li Huo
• Phone: +861069155513
• Email: huoli[@]pumch.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

[18F]Florbetazine ([18F]92) is a molecularly targeted imaging agent for Aβ protein with a novel diaryl-azine scaffold. It has shown specific binding affinity to Aβ aggregates in postmortem human AD brains and excellent brain pharmacokinetic properties with little non-specific retention in white matter in animal studies and a limited number of patients with Alzheimer's Disease (AD). The purpose of the current study is to examine the binding properties of [18F]Florbetazine in human subjects and to compare the cortical and white matter binding with [11C]PiB or [18F]Florbetapir in the same subjects. Imaging of the brain will be completed in healthy adult normal control participants and participants with cognitive impairment (including probable AD and dementia due to other conditions) to characterize [18F]Florbetazine uptake in the brain and its binding properties. [11C]PIB or [18F]Florbetapir PET imaging along with MRI will be completed in the same participants and the data will be compared with 18F-[18F]Florbetazine.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Gender: All
• Age group: 40 Years to 90 Years

Eligibility

Inclusion Criteria:

• Male or Female
• Age = 40 years
• Healthy participants or patients with probable Alzheimer's disease or with dementia due to other causes

Exclusion Criteria:

• Has allergy to [18F]Florbetazine or any of its excipients ;
• Has hypersensitivity to [11C]PIB or any of its excipients ;
• Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ;
• Unwilling or unable to undergo PET scans tracer injections ;
• Unwilling or unable to undergo MRI;
• Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., renal or liver failure, advanced cancer);
• Women who are currently pregnant or breastfeeding;

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Drug:
• [18F]Florbetazine ([18F]92)
Participants will receive a single intravenous bolus injection of 10 mCi ± 20% of the investigational radiotracer [18F]Florbetazine and will undergo a PET/CT scan.
• [11C]PIB
Participants will receive a single intravenous bolus injection of 6.0-20.0mCi of the investigational radiotracer [11C]PIB and will undergo a PET/CT scan.

Locations

Country	Name	City	State
China	Department of Nuclear Medicine, Peking Union Medical College Hopital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The non-displacable binding potential (BPND) of [18F]Florbetazine in healthy participants and patients with probable AD	Dynamic PET data in list-mode is required over 90 minutes in participants. The PET data will be reconstructed into specific dynamic series for kinetic modeling. The non-displacable binding potential (BPND) will be determined in target and reference tissues and compared between healthy participants and patients with probable AD.	1 year
Primary	The distribution volume ratio (DVR) of [18F]Florbetazine in healthy participants and patients with probable AD	Dynamic PET data in list-mode is required over 90 minutes in participants. The PET data will be reconstructed into specific dynamic series for kinetic modeling. The distribution volume ratio (DVR) will be determined in target and reference tissues and compared between healthy participants and patients with probable AD.	1 year
Primary	Comparison of the cortical and white matter binding of [18F]Florbetazine ([18F]92) with [11C]PIB in healthy participants and patients with cognitive decline	[18F]Florbetazine ([18F]92) PET and [11C]PIB PET will be conducted in the same subjects. standardized uptake value ratios of determined cortical and white matter regions will be calculated for both tracers and then compared.	2 years